Last $149.93 USD
Change Today -1.62 / -1.07%
Volume 1.0M
As of 8:04 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 604 0031

Fax:

Perrigo Company provides over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API) in the United States (U.S.), the United Kingdom (U.K.), Mexico, Israel and Australia. The company also distributes in Canada, China and Latin America. Segments The company has four segments, aligned primarily by type of product: Consumer Healthcare (CHC), Nutritionals, Rx Pharmaceuticals, and API. In addition, the company has an Other category that consists of the Israel Pharmaceutical and Diagnostic Products operating segment. Consumer Healthcare The CHC segment manufactures OTC pharmaceutical products. Its major product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and secondary product categories include feminine hygiene, diabetes care and dermatological care. In addition, the fiscal 2013 acquisitions of Sergeant's Pet Care Products, Inc. (Sergeant's) and Velcera, Inc. (Velcera) expanded the company's product portfolio into the animal health category. The CHC business markets products that are comparable in quality and effectiveness to national brand products. The CHC segment markets approximately 2,700 store brand products, with 10,000 stock-keeping units (SKUs), to approximately 1,000 customers. It also manufactures and markets certain products under its Good Sense, Sergeant's, Sentry and PetArmor brands. The company’s U.S.-based customers are major national and regional retail drug, supermarket and mass merchandise chains, including Walmart, CVS, Walgreens, Kroger, Target, Dollar General, Rite Aid, Sam’s Club, Costco, Petco and Petsmart and major wholesalers, including McKesson, Cardinal Health and AmerisourceBergen. Competition: The company’s competitors are Dr. Reddy’s Laboratories, Ltd.; Actavis Inc.; Aaron Industries, Inc.; Ohm Laboratories, Inc.; PL Developments; and LNK International, Inc. Nutritionals The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, vitamin, mineral and dietary supplement (VMS) products, and oral electrolyte solution (OES) products to retailers, distributors and consumers primarily in the U.S., Canada, Mexico and China. The Nutritionals segment markets approximately 900 store brand products, with 3,300 SKUs, to 150 customers. Customers: The company’s U.S.-based customers are major national and regional retail drug, supermarket and mass merchandise chains, including Walmart, CVS, Walgreens, Kroger, Target, Sam’s Club and Costco, as well as major wholesalers, including McKesson. Competition: The company’s competitors for infant formula are Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber) and Danone Baby Nutrition. The company competes in the VMS category with companies, such as Bayer AG, Pfizer, Inc. and Rexall Sundown, Inc. Rx Pharmaceuticals The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription (Rx) drugs primarily for the U.S. market. The company defines this portfolio as predominantly ‘extended topical’ and ‘specialty’ as it encompasses an array of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones and oral solid dosage forms. As a result of the recent acquisition of Rosemont Pharmaceuticals Ltd. (Rosemont) in fiscal 2013, the company expanded its Rx product offering into the U.K. and Europe. Rosemont is a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations. With the acquisition of a product portfolio from Fera Pharmaceuticals, LLC (Fera), the company extended its ophthalmic offerings into the Rx extended topical space. In addition, the Rx Pharmaceuticals segment offers OTC products through the prescription channel (referred to as ‘ORx’ marketing). ORx products are OTC products that are available for pharmacy fulfillment and healthcare rei

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $149.93 USD -1.62

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $62.02 USD +0.49
Forest Laboratories Inc $91.65 USD -0.48
Hospira Inc $43.76 USD +0.05
Mead Johnson Nutrition Co $84.27 USD -0.90
Mylan Inc/PA $50.28 USD +0.43
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 56.7x
Price/Sales 3.9x
Price/Book 2.4x
Price/Cash Flow 79.3x
TEV/Sales 4.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.